Scientific Online Resource System

Scripta Scientifica Medica

Elevated Plasma Levels of Vascular Endothelial Growth Factor and Hepatocyte Growth Factor: Clinical Significance and Correlation with Tumor Burden in Patients with Chronic Myeloid Leukemia

A. Zhelyazkova, L. Gercheva, L. Ivanova


Angiogenesis is an established indispensable process in the development and metastasis of solid tumors. Its significance in the pathogenesis and progression of hematological malignancies is still to be elucidated. Data have recently been accumulated about its role in chornic myeloid leukemia (CML). The aims of our study were: (I) to assess vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) plasma levels in patients with newly diagnosed, untreated and treated CML; (II) to analyze the differences of their levels in varying phases of the disease; (III) to analyze VEGF and HGF correlation with some markers reflecting the tumor burden as well as the progression of the disease. Plasma levels of VEGF and HGF were determined by ELISA in 16 patients with CML and 21 healthy individuals. VEGF and HGF levels were followed-up in 6 patients according to the progression of the disease or the treatment regimen. All the patients with CML showed significantly higher levels of VEGF and HGF when compared to the control group. We found a significant correlation between HGF and leukocytes, LDH, splenomegaly and blast percentage in the peripheral blood. Significant correlation was found between VEGF and platelets, LDH and leukocytes. Our data indicate that CML are highly associated with elevated plasma levels of VEGF and HGF, wich corroborates the thesis of its angiogenic dependency. Likewise, the present study suggests that measurements of VEGF and HGF may be useful for assessing disease activity and progression as well.


Chronic Myeloiud Leukemia; Vascular Endothelial Growth Factor; Hepatocyte Growth Factor; Angiogenesis

Full Text


Folkman, J . The role of angiogenesis in tumor growth.- Semin. Cancer. Biol., 3, 1992, No 2, 65-71.

Salven, H. B., O. E. lversen, L. A. Akslen. Independent prognostic importance of microvessel density in endometrial carcinoma.- Br. .J. Cancer., 77, 1998, 1140-1144.

Fuhrmann-Benzakein, E., M. N. Ma, L. R, Brant, G. Mentha, D. Ruefenachl, A. P. Sappino, M. S. Pepper. Elevated levels of angiogenic cytokines in the plasma of cancer patients.- Int. J. Cancer, 85, 2000, No 1, 40-45.

Aguayo, A., H. Kantarjian, T. Manshuouri, C. Gidel, E. Estey, D. Thomas, C. Koller, Z. Estrov, S. O'Br ien, M. Keating, E. Freireich, M. Albitar. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.- Blood, 96, 2000, No 6, 2240-2245.

Di Raimundo, F., G.Palumbo, S. Molica, R. Giustolishi. Angiogenesis in myeloproliferative disorders.-

Ada Haematol., 106, 2001, 177-183.

Verstovsek, S., H. Kantarjian, T. Manshuour i , J. Cortes, F. J. Giles, A. Rogers, M. Albitar. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia.- Blood, 99, 2002, 2265-2267.

Iwasaki T., T. Hamano, A. Ogata, et al. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma.- Br. J. Haematol., 116, 2002, No 4, 796-802.

Suda, T., N. Takakura, Y. Oike. Hematopoiesis and angiogenesis.- Int. J. Hematol., 71, 2000, No 2, 99-107.

Pelosi, E., M. Valtieri, S. Coppola, R. Botta, M. Gabbianelli, V. Lulli, G. Marziali, B. Masella, R. Muller, C. Sgadari, U.Testa, G. Bonanno, C. Peschle. Identification of the hemangioblast in postnatal life.- Blood, 100, 2002, No 9, 3203-3208.

Fiedler, W., U. Graeven, S. Ergun, S. Verago, N. Kilic, M. Stockschiader , D. K. Hossfeld. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia.- Blood, 89, 1997, No 6, 1870-1875.

Bellamy, W. T., L. Richter, D. Sirjan, C. Roxas, B. Glinsmann-Gibson, Y. Frutiger, T. M. Grogan, A. F. List. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.- Blood, 97, 2001, No 5, 1427-1434.

Nishino, T., H. Hisha, N. Nishino, M. Adachi, S. Ikehara. Hepatocyte growth factor as a hematopoietic regulator.- Blood, 85, 1995, 3093 (Abstract).

Weimar, I. S., C. Voermans , J. H. Bourhis, N. Miranda, P. C. M. Berk, T. Nakamura, G C. Gast, W. R. Gerritsen. Hepatocytegrowth factor/scatter factor (HGF/SF) affects proliferation and migration of myeloid leukemic cells.- Leukemia 12, 1998, No 8, 1195-1203.

Zhelyazkova, A., L. Gercheva, L. Ivanova, N. Tzvetkov, A. Antonov. Elevated plasmatic levels of VEGF and HGF in patients with chronic myeloproliferative disorders.- Clin. Transf. Haematol., 39, 2003, No 3-4, 24-31.

Jelkmann, W. Pitfalls in the measurement of circulating vascular endothelial growth factor.- Clin. Chern.. 47, 2001, No 4, 617-623.

Krauth M.T., I. Simonitsh, M. Mayerhofer, W. R. Sperr, C. Sillaber, B. Schneeweiss, G. Mann, H. Gadner, P. Valent. Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with phase of disease.- Am. J. Clin. Pathol, 121, 2004, No 4,473-481.



Article Tools
Email this article (Login required)
About The Authors

A. Zhelyazkova


L. Gercheva


L. Ivanova


Font Size